John R. Atack
Merck Sharp & Dohme Research Laboratories
Neuroscience Research Centre
Terlings Park
Eastwick Road
United Kingdom
Name/email consistency: high
- TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. Atack, J.R., Wafford, K.A., Tye, S.J., Cook, S.M., Sohal, B., Pike, A., Sur, C., Melillo, D., Bristow, L., Bromidge, F., Ragan, I., Kerby, J., Street, L., Carling, R., Castro, J.L., Whiting, P., Dawson, G.R., McKernan, R.M. J. Pharmacol. Exp. Ther. (2006)
- The proconvulsant effects of the GABAA alpha5 subtype-selective compound RY-080 may not be alpha5-mediated. Atack, J.R., Bayley, P.J., Fletcher, S.R., McKernan, R.M., Wafford, K.A., Dawson, G.R. Eur. J. Pharmacol. (2006)
- Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors. Atack, J.R., Hutson, P.H., Collinson, N., Marshall, G., Bentley, G., Moyes, C., Cook, S.M., Collins, I., Wafford, K., McKernan, R.M., Dawson, G.R. Br. J. Pharmacol. (2005)
- The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Atack, J.R. Expert. Opin. Investig. Drugs (2005)
- In vivo labelling of alpha5 subunit-containing GABA(A) receptors using the selective radioligand [(3)H]L-655,708. Atack, J.R., Alder, L., Cook, S.M., Smith, A.J., McKernan, R.M. Neuropharmacology (2005)
- Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. Atack, J.R. Curr. Drug. Targets. CNS. Neurol. Disord (2003)
- Inositol monophosphatase activity in normal, Down syndrome and dementia of the Alzheimer type CSF. Atack, J.R., Schapiro, M.B. Neurobiol. Aging (2002)
